TB-500

Summary

TB-500 is a lab-made peptide marketed for injury recovery, especially for muscle, tendon, and ligament repair. The single most important thing to understand about it is a naming problem: TB-500 is a short 7-amino-acid synthetic fragment (sequence Ac-LKKTETQ) of a natural 43-amino-acid protein called thymosin beta-4 (Tβ4). Vendors and forums use "TB-500" and "thymosin beta-4" interchangeably, but they are not the same molecule — and that distinction is where most of the misleading marketing lives. The genuine human clinical research is on the full Tβ4 protein, usually as a topical eye drop, not on injectable TB-500 for sports recovery.

What people use it for

In athlete, bodybuilding, and biohacker communities, TB-500 is used (by injection, subcutaneous or intramuscular) for soft-tissue injuries — muscle strains, tendon and ligament damage, post-surgical recovery, joint pain — and as a general "systemic healing" and anti-inflammatory aid. It is frequently paired with BPC-157. These are the claims the evidence sections test; describing them is not endorsement.

Human evidence

For TB-500 itself — the injectable fragment people actually buy — there is essentially no human efficacy evidence. As of 2026, no completed, published human trial has tested the TB-500 fragment for muscle, tendon, ligament, or any other tissue-repair use. Reviewers who have looked specifically at this point are blunt that the published clinical work is in ophthalmology and cardiology, not in tendon or muscle recovery, and that going from "thymosin beta-4 helps corneal wounds" to "TB-500 will heal my tendon" is an untested leap.

What human data does exist is on the full-length Tβ4 protein, and mostly as a topical eye treatment. RegeneRx's RGN-259 (a 0.1% thymosin β4 eye drop) has been through Phase 2 and Phase 3 trials for dry eye disease and neurotrophic keratopathy. The results are real but modest and mixed. A 2015 Phase 2 randomized, double-masked, placebo-controlled trial reported that the eye drops improved signs and symptoms of severe dry eye — but it enrolled only nine patients, so it is a promising signal rather than definitive proof. In a later Phase 3 neurotrophic-keratopathy trial, complete corneal healing occurred in 6 of 10 treated patients versus 1 of 8 on placebo — again a strong trend in a very small sample — while a separate Phase 3 (SEER-3) did not meet its primary endpoint, and an earlier dry-eye Phase 2 missed both of its pre-specified primary endpoints despite some positive secondary measures.

Beyond the eye, the first-in-human safety data for systemic thymosin β4 is recent and narrow. A 2021 first-in-human Phase 1 study gave intravenous recombinant full-length Tβ4 (single and multiple doses) to 54 healthy volunteers and reported it was well tolerated and safe, as a step toward testing it in acute myocardial infarction; this was a safety/pharmacokinetic study, not an efficacy trial, and again used the full protein rather than the TB-500 fragment. A small cardiac pilot using thymosin β4 in heart-attack patients has also been reported. None of this involved injecting the TB-500 fragment for athletic recovery, and it should not be read as evidence for that use. It is included here precisely because this body of full-Tβ4 research is so often borrowed to sell something it didn't test.

Animal / preclinical evidence

The preclinical case is moderate and mechanistically plausible, but it leans heavily on the parent protein. In rodent models, thymosin β4 (and, in some studies, short actin-binding fragments) has been associated with faster skeletal-muscle regeneration, reduced fibrotic scarring, and improved tendon strength and collagen organization versus controls; equine tendon-injury work has reported similar acceleration. The proposed mechanism is consistent across these studies and is summarized in mechanism reviews: Tβ4 binds and sequesters G-actin, which supports cell migration and cytoskeletal remodeling, and it appears to promote angiogenesis and dampen apoptosis and inflammation — all relevant to repairing poorly-vascularized tissue like tendon. Work specifically on the TB-500 fragment is thinner and more basic: a 2024 analytical-chemistry study, for instance, quantified TB-500 and its breakdown products in cells and rats and screened them for wound-healing activity in vitro — useful for confirming the fragment is biologically active in a dish, but a long way from demonstrating clinical benefit in people.

The translational caveats are larger here than for many peptides: much of the foundational work used full-length Tβ4 rather than the TB-500 fragment, so applying it to TB-500 adds a second layer of extrapolation (animal → human, and full protein → fragment). Whether the 7-amino-acid fragment reproduces the full protein's effects at typical doses is not settled.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Users commonly report faster recovery from nagging soft-tissue injuries over a few weeks of use, based on personal experience rather than controlled testing. TB-500 and BPC-157 are widely marketed together as a so-called "Wolverine stack" for accelerated whole-body healing. There is no controlled human study of that combination, and no FDA-approved or clinically validated protocol for combining the two; the only place the pair appears together in published human data is a small, uncontrolled retrospective knee-pain chart review (discussed in the BPC-157 brief), which cannot isolate either peptide's effect, let alone the combination's. Treat the "stack" as an unverified community protocol, not an evidence-based one.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

There is no established or validated human dose for the TB-500 fragment, because there are no completed human efficacy trials of it. The human dosing that does exist is for a different product and route: RGN-259 is a 0.1% thymosin β4 topical ophthalmic solution used in eye-drop trials, not an injected systemic dose. Community injection "protocols" circulating online are not derived from published human trials and are not reported here as guidance. Because product is sold gray-market, what is actually in a given vial is also uncertain.

Safety & side effects

The human safety profile of injectable TB-500 is not established. The FDA states it "has not identified any human exposure data" for the thymosin beta-4 fragment and therefore lacks the information to know whether it would cause harm in humans; it also flags potential immunogenicity (immune reactions) and peptide-impurity concerns. In the full-Tβ4 eye-drop trials, the topical product was generally well tolerated with no significant adverse effects reported — but that is a topical formulation of a different molecule and does not establish the safety of systemic injection. As with other angiogenesis-promoting peptides, there is a theoretical concern that stimulating new blood-vessel growth could support tumor growth; this has not been demonstrated in humans, and sources note no direct TB-500–cancer link has been established, but it is a reason caution is advised for anyone with cancer concerns. A separate, concrete risk is product quality: gray-market vials are unregulated and may be contaminated, mislabeled, or inaccurately dosed, and some "TB-500" products may not contain the stated peptide at all.

Regulatory / legal status

TB-500 is not FDA-approved for any use and is not a lawful dietary ingredient. Its compounding status mirrors BPC-157's and is in flux: the FDA lists it as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" and removed it from compounding "Category 2" in April 2026 — but only because the nominations to add it to the approved 503A bulks list were withdrawn, a procedural change that does not on its own authorize pharmacies to compound it. TB-500 is on the agenda for the FDA Pharmacy Compounding Advisory Committee meeting of July 23–24, 2026, which will consider whether it should be added to the 503A list; only a favorable recommendation followed by a final FDA rule would make legal compounding possible. Until then it reaches consumers through unregulated research-chemical channels. Note the distinction from full-length thymosin β4, which has been studied under an investigational new drug (IND) pathway (e.g., the RGN-259 eye-drop program) but is likewise not FDA-approved for any indication.

In sport, the World Anti-Doping Agency prohibits TB-500 (and thymosin β4 and related fragments) at all times, in and out of competition, within its peptide/growth-factor provisions; athletes have been sanctioned for its use. Status varies by country and can change; this is not legal advice.

Podcast / media mentions

TB-500 shows up in the same fitness-and-longevity media ecosystem as BPC-157, usually as its "healing stack" partner, and it benefits from a particular sleight of hand: promoters cite the legitimate thymosin β4 research base — decades of preclinical work and the RegeneRx eye-drop trials — and let the credibility of the full protein transfer onto the injectable fragment they're selling. The fair critique is of that move, not of any individual: the research that sounds impressive is largely on a different molecule (full Tβ4), a different route (topical), and a different indication (corneal/ocular healing), and even there the results are mixed. For the use TB-500 is actually marketed for — injecting it to heal muscles and tendons — the honest summary is that the human evidence does not exist yet.